The AI-Mind consortium meets for 9th General Assembly
The AI-Mind consortium will host its 9th General Assembly (GA9) at the Universidad Complutense de Madrid (UCM) from October 28-29, 2024. The assembly, which gathers researchers and consortium members, will focus on assessing project progress, refining strategies for the future, and advancing AI-based tools for early detection of cognitive impairment and dementia. The GA will span one and a half days and will feature a joint dinner on the evening of October 28, designed to foster team cohesion and facilitate further discussions.
Key Topics and Structure
GA9 will feature presentations from each of AI-Mind’s work packages, highlighting essential updates, challenges, and progress made across various areas, from data management and AI modelling to clinical trials and health technology assessment. In addition to the WP presentations, GA9 will feature intermediate workshops and Q&A sessions that focus on technical issues, data analysis, and collaborative efforts within the consortium. These sessions are designed to enhance communication across work packages and ensure that the project remains on track to meet its objectives.
Expert Guest Lectures
A highlight of GA9 will be two guest lectures from prominent experts in the field of cognitive health:
- Paolo Maria Rossini will present on “Why and Where Neurophysiological Approaches Are More Informative than Traditional Neuroimaging,” offering valuable insights into the advantages of neurophysiological methods in studying cognitive impairment. His expertise is expected to enrich discussions on how these approaches can complement AI-Mind’s work.
- Giovanni Frisoni, a leading figure in Alzheimer’s and neuroimaging research, will share his expertise on advancing early detection strategies for neurodegenerative diseases. His lecture will contribute to shaping the consortium’s long-term research objectives.
Strategic vision for the future
An important focus of GA9 will be on shaping the future of AI-Mind, specifically discussing plans for extending the project’s work beyond 2025. Discussions will emphasize how ongoing research can solidify a cohesive vision for the future and ensure continuity in developing AI-driven diagnostic tools for cognitive health.
Continuing at 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference
At the CTAD 2024 Conference from 29 October to 1 November, the AI-Mind consortium will present a series of research posters that highlight their contributions to advancing the field of cognitive impairment and Alzheimer’s disease research. These presentations will feature findings from the project, including an exploration of the associations between cognitive impairment, ApoE genotype, and plasma p-tau biomarkers in European mild cognitive impairment populations. Read about what is planned at the event page.
Conclusion
GA9 in Madrid represents a pivotal point for the AI-Mind consortium, combining formal presentations, expert insights, and collaborative workshops with contributions to the key conference in the field – CTAD. With a focus on fostering partnerships and planning for the project’s future, the assembly will ensure AI-Mind remains at the forefront of research into early cognitive impairment detection. Stay tuned for the updates after the meeting.